[go: up one dir, main page]

DK1521831T3 - Transgent dyr der udtrykker trunkeret alzheimers tauprotein - Google Patents

Transgent dyr der udtrykker trunkeret alzheimers tauprotein

Info

Publication number
DK1521831T3
DK1521831T3 DK03763764T DK03763764T DK1521831T3 DK 1521831 T3 DK1521831 T3 DK 1521831T3 DK 03763764 T DK03763764 T DK 03763764T DK 03763764 T DK03763764 T DK 03763764T DK 1521831 T3 DK1521831 T3 DK 1521831T3
Authority
DK
Denmark
Prior art keywords
molecules
amino acids
terminal amino
alzheimer
tau
Prior art date
Application number
DK03763764T
Other languages
English (en)
Inventor
Peter Filipcik
Eva Kontsekova
Original Assignee
Axon Neuroscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Neuroscience filed Critical Axon Neuroscience
Application granted granted Critical
Publication of DK1521831T3 publication Critical patent/DK1521831T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Knock-in vertebrates, e.g. humanised vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/15Humanized animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0306Animal model for genetic diseases
    • A01K2267/0312Animal model for Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
DK03763764T 2002-07-12 2003-07-09 Transgent dyr der udtrykker trunkeret alzheimers tauprotein DK1521831T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT10532002 2002-07-12
PCT/EP2003/007390 WO2004007722A2 (en) 2002-07-12 2003-07-09 Transgenic animal expressing alzheimer’s tau protein

Publications (1)

Publication Number Publication Date
DK1521831T3 true DK1521831T3 (da) 2008-06-30

Family

ID=30120907

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03763764T DK1521831T3 (da) 2002-07-12 2003-07-09 Transgent dyr der udtrykker trunkeret alzheimers tauprotein
DK03763763T DK1521774T3 (da) 2002-07-12 2003-07-09 Trunkerede Tau-proteiner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK03763763T DK1521774T3 (da) 2002-07-12 2003-07-09 Trunkerede Tau-proteiner

Country Status (10)

Country Link
US (5) US8288608B2 (da)
EP (3) EP1521831B1 (da)
JP (3) JP4414332B2 (da)
CN (2) CN100577803C (da)
AT (2) ATE391781T1 (da)
AU (2) AU2003246664B2 (da)
DE (2) DE60323231D1 (da)
DK (2) DK1521831T3 (da)
ES (2) ES2304146T3 (da)
WO (2) WO2004007547A2 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1521831T3 (da) * 2002-07-12 2008-06-30 Axon Neuroscience Transgent dyr der udtrykker trunkeret alzheimers tauprotein
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7609947B2 (en) 2004-09-10 2009-10-27 Panasonic Corporation Method and apparatus for coordinating playback from multiple video sources
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体,其相关产品,生产所述抗体的方法,所述抗体的应用以及使用方法
ES2453941T5 (es) 2005-11-30 2017-05-31 Abbvie Inc. Anticuerpos monoclonales contra la proteína beta amiloide y usos de los mismos
KR100734815B1 (ko) 2006-02-15 2007-07-09 대한민국 Htau24 유전자를 발현하는 형질전환 치매 마우스 및 그제조방법
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
CN102058619A (zh) * 2010-12-08 2011-05-18 山西医科大学 一种阿尔茨海默病复合动物模型的制备方法
AU2011352333B2 (en) * 2010-12-31 2016-12-08 Zeus Scientific, Inc. Improved methods for determining cell viability using molecular nucleic acid-based techniques
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
EP2709728B1 (en) * 2011-05-20 2019-01-23 Oligomerix, Inc. Tau protease methods of use
SG10201912955PA (en) 2011-09-19 2020-02-27 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
KR20200013072A (ko) 2012-07-03 2020-02-05 워싱턴 유니버시티 Tau에 대한 항체
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
WO2015122922A1 (en) 2014-02-14 2015-08-20 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
TW202136296A (zh) 2014-06-27 2021-10-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
RU2730668C2 (ru) 2014-11-19 2020-08-24 Аксон Ньюросайенс Се Гуманизированные тау-антитела при болезни альцгеймера
SG11201706293XA (en) * 2015-02-04 2017-09-28 Hoffmann La Roche Tau antisense oligomers and uses thereof
WO2017172764A1 (en) * 2016-04-01 2017-10-05 The Regents Of The University Of California Modified cell line and method of determining tauopathies
KR101997319B1 (ko) 2016-06-21 2019-07-08 전남대학교산학협력단 이형태체 항원인식 항체 생산을 유도하는 플라젤린 백신보조제 기반의 백신의 제조 및 그 응용
WO2018126180A1 (en) * 2016-12-30 2018-07-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for the detection of tau protein aggregates
EP3599842B1 (en) * 2017-03-21 2024-08-07 The Jackson Laboratory A genetically modified mouse expressing human apoe4 and mouse trem2.p.r47h and methods of use thereof
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. CANCER TREATMENT BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
MX2020009991A (es) 2018-03-28 2020-10-14 Axon Neuroscience Se Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer.
US11155609B2 (en) 2019-04-05 2021-10-26 TauC3 Biologies Limited Anti-TAUC3 antibodies and uses thereof
KR102509648B1 (ko) 2019-08-06 2023-03-15 아프리노이아 테라퓨틱스 리미티드 병리학적 타우 종에 결합하는 항체 및 이의 용도
CN110679549B (zh) * 2019-11-05 2021-08-20 南通大学 一种阿尔茨海默病小鼠模型的构建方法
AU2022348935A1 (en) * 2021-09-24 2024-04-04 Alnylam Pharmaceuticals, Inc. Microtubule associated protein tau (mapt) irna agent compositions and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06239899A (ja) 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
AU4322999A (en) 1998-06-01 1999-12-20 Advanced Research And Technology Institute, Inc. Methods and compositions for diagnosing tauopathies
NZ515956A (en) * 1999-07-02 2004-04-30 Janssen Pharmaceutica Nv Transgenic animals as models for neurodegenerative disease
ATE326700T1 (de) * 1999-09-09 2006-06-15 Max Planck Gesellschaft SCREENING NACH INHIBITOREN VON ßGEPAARTEN HELIKALEN FILAMENTENß
AU2001229619A1 (en) * 2000-01-21 2001-07-31 Pharmacia And Upjohn Company Transgenic mouse model of human neurodegenerative disease
WO2001065252A1 (en) * 2000-02-29 2001-09-07 The Nathan S. Kline Institute For Psychiatric Research Transgenic mice comprising a genomic human tau transgene
GB0100119D0 (en) * 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
AT500379B8 (de) * 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US20020164657A1 (en) * 2001-02-23 2002-11-07 Sharma Satish K. Assays for assessing A beta-Tau aggregation
DK1521831T3 (da) * 2002-07-12 2008-06-30 Axon Neuroscience Transgent dyr der udtrykker trunkeret alzheimers tauprotein

Also Published As

Publication number Publication date
EP1521774B1 (en) 2008-08-27
DE60320258T2 (de) 2009-06-25
WO2004007547A2 (en) 2004-01-22
AU2003246664A1 (en) 2004-02-02
DE60320258D1 (de) 2008-05-21
US9161520B2 (en) 2015-10-20
ATE391781T1 (de) 2008-04-15
EP1521774A2 (en) 2005-04-13
US20060167227A1 (en) 2006-07-27
EP1521831A2 (en) 2005-04-13
CN100572392C (zh) 2009-12-23
US9485972B2 (en) 2016-11-08
US20060112437A1 (en) 2006-05-25
JP2006515270A (ja) 2006-05-25
WO2004007547A3 (en) 2004-07-22
CN1668745A (zh) 2005-09-14
US20160106077A1 (en) 2016-04-21
US20100063250A1 (en) 2010-03-11
JP2009143906A (ja) 2009-07-02
JP2005532802A (ja) 2005-11-04
JP4414332B2 (ja) 2010-02-10
CN100577803C (zh) 2010-01-06
DK1521774T3 (da) 2008-10-27
AU2003253044A1 (en) 2004-02-02
US8288608B2 (en) 2012-10-16
CN1668641A (zh) 2005-09-14
EP1995255A1 (en) 2008-11-26
ATE406383T1 (de) 2008-09-15
EP1521831B1 (en) 2008-04-09
ES2304146T3 (es) 2008-09-16
AU2003253044B2 (en) 2009-08-13
US20130179997A1 (en) 2013-07-11
ES2311734T3 (es) 2009-02-16
WO2004007722A3 (en) 2004-03-25
AU2003246664B2 (en) 2007-06-14
JP4308760B2 (ja) 2009-08-05
WO2004007722A2 (en) 2004-01-22
DE60323231D1 (de) 2008-10-09

Similar Documents

Publication Publication Date Title
DK1521831T3 (da) Transgent dyr der udtrykker trunkeret alzheimers tauprotein
ATE517915T1 (de) Methode zur identifikation gen-regulierender peptide
ATE169304T1 (de) Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
CY1106899T1 (el) Διαμορφωτες συσσωματωσης βητα-αμυλοειδων πεπτιδιων που περιλαμβανουν d-αμινοξεα
AT500379B8 (de) Tau-proteine
DE60128916D1 (de) Neues, physiologisch aktives peptid und dessen verwendung
CY1108182T1 (el) Μεσα εντοπισμου του παθολογικου μετασχηματισμου της πρωτεϊνης app και εφαρμογες τους
DE60121346T8 (de) Suppressor-Gen
CY1110185T1 (el) Τροποποιημενη πρωτεϊνη vp1-καψιδιου του παρβοϊου β19
ATE319819T1 (de) Humane hirn-spezifische carboxypeptidase b
WO2004017992A3 (en) Ptk7 protein involvement in carcinoma
ATE485831T1 (de) Behandlung von neurodegeneration
ATE346091T1 (de) Neues diagnostisches reagens und kit zur erkennung von rickettsiose
BRPI0308978A8 (pt) fragmentos de peptídeos sintéticos ativos
DE69712182D1 (de) Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises
DE60321443D1 (de) Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung
WO2001067097A3 (en) Method of identifying modulators of presenilin
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
ATE260934T1 (de) Therapeutische peptide aus untersequenzen von bpi
ATE447045T1 (de) Assoziation von proteinpolymorphismen mit koronarer herzkrankheit
DZ2803A1 (fr) Polypeptide de la protéine c humaine.
DE60136688D1 (de) Partnern des ptb1 domäne aus fe65, herstellung und verwendungen davon
ATE336503T1 (de) Cyclophilin als allergen identifiziert